Patient Preference Following Treatment with Dupilumab and Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Multicenter Retrospective Analysis
收藏Mendeley Data2026-08-04 收录
官方服务：
资源简介：
Supplemental Table 1: Summary of Patient Demographics including age, sex, length of trial on dupilumab, length of trial on lebrikizumab Supplemental Table 2: Outcomes after switching from Dupilumab to Lebrikizumab stratified by reason for switching from Dupilumab.
创建时间：
2026-08-03
